Astronomy show accidentally reveals unseen structure in our solar system
An accidental discovery might change how we think about one of the most mysterious structures in our solar system.
The Oort Cloud, a large expanse of icy bodies revolving around the sun at a distance 1,000 times greater than the orbit of Neptune, is widely thought to be spherical — although it has never been directly observed.
But during the preproduction of a show titled 'Encounters in the Milky Way,' which debuted Monday at the Hayden Planetarium in New York City, a projection on the planetarium's dome revealed something strange within the Oort Cloud: a spiral.
The curators were testing out a scene in September that includes a detailed view of Earth's celestial neighborhood — from the sun to the solar system's outer edges — and were surprised when they saw the structure, which looked coincidentally similar to a spiral galaxy such as our own.
'We hit play on the scene, and immediately we saw it. It was just there,' recalled Jackie Faherty, an astrophysicist at the American Museum of Natural History and the curator of the show. 'I was confused and thought that was super weird. I didn't know if it was an artifact, I didn't know if it was real.'
To investigate, Faherty got in touch with David Nesvorny, an institute scientist with the Southwest Research Institute in Boulder, Colorado, and the Oort Cloud expert who had provided scientific data for the scene.
'We didn't create it — David did,' Faherty said. 'This is David's simulation, and it's grounded in physics. It has a totally good physical explanation for why it should be there.'
At first, Nesvorny suspected artifacts — abnormalities or distortions in the data visualization — but once he looked at his data, he confirmed the presence of the spiral and eventually published a scientific paper about the discovery in April in The Astrophysical Journal. 'Weird way to discover things,' he said. 'I should know my data better, after years of working with it.'
Crazy, long orbits
The existence of the Oort Cloud was first proposed in 1950 by Dutch astronomer Jan Oort, who imagined it as a shell of icy bodies swirling around the sun from up to 1.5 light-years away. The cloud is the most distant region in our solar system, stretching as much as halfway to the next star, according to NASA.
Spiral structure
The spiral structure, visible here behind the sun in a scene from the show, surprised scientists and animators when they saw it projected on the planetarium's dome during preproduction. AMNH via CNN Newsource
It's composed of leftovers from the making of our solar system, which were scattered in every direction by the planets after they formed. That means many of the icy bodies in the Oort Cloud don't share the same orbital plane as the solar system itself but travel at various inclinations, which is why the Oort Cloud is pictured as a sphere. If one of those icy bodies gets flung inward toward the sun, the heat starts vaporizing some of the material in the body, creating a tail — and what we call a comet.
'Every now and again, some of these icy bodies come into the inner solar system, and we can see the orbit that they're on,' Faherty said. 'And they're on these really crazy, long orbits. It can take them millions of years to go around the sun. And when they come in, they help us understand how far away they may have come from.'
The problem with trying to imagine what the Oort Cloud looks like is that scientists have never seen it, even though we are technically surrounded by it. That's because the bodies that make it up are small — fewer than 60 miles (97 kilometers) in diameter — and even though they potentially number in the trillions, they are far away, making observations with telescopes difficult.
The spiral was hiding in Nesvorny's data because he had never thought of visualizing it three-dimensionally. 'I never looked at it in Cartesian coordinates — I didn't have a good reason to do so,' he said. 'But once you do that, it's obvious. It's there.'
The galactic tide
To confirm the findings, Nesvorny used one of the most powerful computers in the world, NASA's Pleiades Supercomputer, to run simulations that took weeks to complete.
'I thought, maybe just this particular simulation (I gave the planetarium) is showing it, and all the other simulations with other stellar encounters, other parameters, will not show it, in which case it wouldn't be so interesting,' he said. 'But all the simulations, all the models I have, show the spiral.'
The reason it's there, he said, is that objects in the Oort Cloud are far away enough from the sun's gravity that they also start being affected by the galactic tide — the gravitational field of our galaxy, exerted by the stars and the dark matter in it. This field is acting on the small bodies and comets in the Oort Cloud by twisting their orbital planes to create a spiral.
The spiral, Nesvorny added, is in the inner part of the Oort Cloud, the closest to us, and he still believes that the outer portion is spherical or shell-shaped.
The problem of observing the Oort Cloud remains, even though the Vera C. Rubin Observatory, a powerful telescope that recently came online in Chile, could offer a hand by discovering and observing individual icy bodies in the cloud. However, according to Nesvorny, the telescope will likely discover dozens of these bodies — not the hundreds that would be required to produce a meaningful visualization of the spiral.
The spiral theory helps to illuminate the dynamics of our solar system, according to Faherty. 'If you're going to come up with a theory of how solar systems evolve, you should take into account the kind of shapes you might have in their structure,' she said. 'Maybe comets helped deliver water to Earth. Maybe the building blocks of life could be out there in the Oort Cloud, so if you want to talk about the potential building blocks of life that surround our solar system, you need to understand its shape.'
Vera C. Rubin Observatory
The Vera C. Rubin Observatory, located in the Tololo hill near La Serena, Chile, will survey the night sky during its 10-year mission and could greatly expand scientists' understanding of the Oort Cloud. Javier Torres/AFP/Getty Images via CNN Newsource
It's a 'dream,' she added, to be able to present science so recent in a show aimed at the general public. 'I truly believe that the planetarium, the dome itself, is a research tool,' Faherty said. 'I like to say that this is science that hasn't had time to reach your textbook yet.'
Viewing what's not visible
The spiral finding is a wonderful example of just how much we can learn through visualizing the universe in new ways, said Malena Rice, an assistant professor of astronomy at Yale University who did not participate in the study.
'This result reshapes our mental image of our home solar system, while also providing a new sense for what extrasolar systems' Oort clouds may look like,' Rice added. 'It unites our models of the solar system with what we know about the broader galaxy, placing it into context as a dynamic system. We are not static, and we are not isolated — our solar system is shaped by its broader ecosystem, and the Oort spiral exemplifies that.'
While the paper is interesting, it is almost entirely theoretical, as it is based on numerical simulations of the interactions between the sun's gravity and the gravitational pull of the rest of the Milky Way galaxy's motion, said Edward Gomez, an astrophysicist and honorary lecturer at Cardiff University in the UK. He also was not involved with the study.
'Long period comets enter the inner solar system at a range of angles, which the authors try to model using their spiral arm idea,' Gomez said in an email. 'What they are proposing could be true, but it could also be modelled by other shapes of the Oort cloud or physical processes. How to test this is their major issue, because only a handful of potential Oort cloud objects are known about.'
Confirming the findings will be a challenge, noted Simon Portegies Zwart, a professor of numerical star dynamics at Leiden University in the Netherlands who was not part of the team behind the research. 'It is interesting that they found the spiral, (but) it seems unlikely that we are going to witness (it) in the foreseeable future,' he said.
With luck, he added, the Vera Rubin observatory will detect a few hundred inner Oort Cloud objects, but the spiral would only be visible if many more are found: 'It therefore seems unlikely to be a clearly detectable structure.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
3 hours ago
- Globe and Mail
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Globe and Mail
4 hours ago
- Globe and Mail
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors' Dallas, Texas - The Dr. Michael Rimlawi Scholarship for Future Doctors is now open for applications, offering a meaningful academic opportunity to undergraduate students across the United States who are committed to pursuing a career in medicine. Spearheaded by renowned spine surgeon Dr. Michael Rimlawi, this scholarship reflects a deep commitment to supporting the next generation of healthcare leaders who are ready to make a difference in the field of medicine. The scholarship is designed for undergraduate students enrolled at accredited colleges or universities who have set their sights on a future in healthcare. In line with Dr. Michael Rimlawi's dedication to innovation and mentorship in the medical field, the program encourages thoughtful reflection on personal inspiration and the impact future doctors wish to have in the profession. To be considered, applicants must submit an original essay between 500 and 750 words responding to the prompt: 'What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?' Essays will be evaluated on clarity, originality, and depth of insight. The deadline for application submissions is January 15, 2026, and the scholarship recipient will be announced on February 15, 2026. Dr. Michael Rimlawi, who is widely respected for his pioneering contributions in minimally invasive spine surgery, brings both clinical excellence and visionary leadership to the scholarship initiative. As a physician who has led advancements in micro-endoscopic techniques and was the first in the nation to perform the Globus Minimally Invasive XLIF procedure, Dr. Rimlawi understands the transformative impact of dedication and continuous learning in medicine. Through this scholarship, Dr. Michael Rimlawi aims to help lessen the financial burden for students who demonstrate not only academic determination but also a clear vision for how they intend to shape the healthcare system in meaningful ways. The scholarship is not limited by geographic region and is open to qualified undergraduate students throughout the United States. 'Mentoring future doctors has always been a personal mission,' says Dr. Michael Rimlawi, who has long advocated for educational support as a means to uplift future medical professionals. By launching this scholarship, Dr. Michael Rimlawi seeks to provide more than financial aid—he offers recognition and encouragement to students committed to advancing patient-centered care. The Dr. Michael Rimlawi Scholarship for Future Doctors continues to grow as an extension of Dr. Rimlawi's broader mission: to foster innovation, compassion, and progress within the healthcare system by investing in students who will become the physicians of tomorrow. Applicants interested in this opportunity are encouraged to visit the official website to review the full eligibility criteria and submit their essays through the application portal. For more details or to apply, visit below. Media Contact Company Name: Dr. Michael Rimlawi Scholarship Contact Person: Dr. Michael Rimlawi Email: Send Email City: Dallas State: Texas Country: United States Website:


CTV News
5 hours ago
- CTV News
Be shark smart at the beach
Atlantic Watch Shark sightings are rare, but beachgoers are still encouraged to be shark smart.